Publications by authors named "A de Labriolle"
Article Synopsis
- Patients who need oral anticoagulation and undergo coronary intervention can use a special stent (COBRA PzF) that may lower the need for long-term dual antiplatelet therapy (DAPT) while maintaining safety against blood clots.
- In a study, 996 patients were randomized to receive either the COBRA PzF stent with a short 14-day DAPT or a regular stent with longer DAPT durations of 3 to 6 months.
- Results showed that the COBRA stent did not significantly reduce bleeding compared to the control group and was not proven to maintain equivalent safety for thromboembolic events, indicating further investigation is needed.
Background: Randomized trials comparing the first-generation absorb bioresorbable vascular scaffold (BVS) (Abbott Vascular, Santa Clara, CA, USA) with a drug-eluting stent showed a moderate but significant increase in the rate of 3-year major adverse cardiac events and scaffold thrombosis, followed by a decrease in adverse events after 3 years.
Aim: The objective of this study was to assess the 5-year outcomes of patients treated with at least one absorb BVS and included in the FRANCE ABSORB registry.
Methods: All patients treated in France with an absorb BVS were prospectively included in a large nationwide multicentre registry.
Background: The Cobra PzF coronary stent is cobalt chromium with flat thin struts, nano-coated with Polyzene-F that enhance rapid reendothelialization and reduce the risk of stent thrombosis and restenosis. It is designed to overcome shortfalls of BMS and DES in patients requiring short DAPT duration.
Aims: To report procedural and 1-year clinical outcomes following Cobra PzF stent implantation in routine practice PCI.
Aims: Current guidelines recommend short time delays from qualifying ECG to reperfusion therapy in ST-elevation myocardial infarction (STEMI) patients. Recently, however, it has been suggested that shortening door-to-balloon times might not result in lower mortality, thereby questioning the relevance of current guidelines. The aim of this study was to assess in-hospital and one-year mortality in patients with fibrinolysis or primary percutaneous coronary intervention (PPCI) according to guidelines-recommended times to reperfusion therapy.
View Article and Find Full Text PDFThe P2Y12-ADP receptor antagonists are the cornerstone of oral antiplatelet therapy in the secondary prevention of coronary artery disease, especially after acute coronary syndrome or percutaneous coronary intervention. Currently, the therapeutic agents available to block the receptor include clopidogrel and prasugrel; ticagrelor is not available everywhere. Clopidogrel was the gold standard, but recently it has been challenged by prasugrel and ticagrelor.
View Article and Find Full Text PDF